ES2039237T3
(es)
*
|
1986-04-24 |
1993-09-16 |
Fujisawa Pharmaceutical Co., Ltd. |
Procedimiento para preparar nuevos compuestos de acido difosfonico.
|
ES2039259T3
(es)
*
|
1986-11-21 |
1993-09-16 |
Ciba-Geigy Ag |
Procedimiento para la obtencion de acidos azacicloalquil alcandifosfonicos aromaticamente substituidos.
|
DE3640938A1
(de)
*
|
1986-11-29 |
1988-06-01 |
Boehringer Mannheim Gmbh |
Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindung enthaltende arzneimittel
|
US5190930A
(en)
*
|
1987-12-11 |
1993-03-02 |
Ciba-Geigy Corporation |
Araliphatylaminoalkanediphosphonic acids
|
US5110807A
(en)
*
|
1988-12-01 |
1992-05-05 |
Ciba-Geigy Corporation |
Araliphatylaminoalkanediphosphonic acids
|
US7452359B1
(en)
*
|
1988-06-13 |
2008-11-18 |
Warsaw Orthopedic, Inc. |
Apparatus for inserting spinal implants
|
US5316770A
(en)
*
|
1989-02-16 |
1994-05-31 |
University Of Georgia Research Foundation, Inc. |
Vitamin D derivative feed compositions and methods of use
|
AU5185790A
(en)
*
|
1989-02-16 |
1990-09-05 |
University Of Georgia Research Foundation, Inc., The |
Treatment of tibial dyschondroplasia
|
US5366736A
(en)
*
|
1989-02-16 |
1994-11-22 |
University Of Georgia Research Foundation, Inc. |
Vitamin D derivative feed compositions and methods of use
|
MX21452A
(es)
*
|
1989-07-07 |
1994-01-31 |
Ciba Geigy Ag |
Preparaciones farmaceuticas que se administran en forma topica.
|
US5139786A
(en)
*
|
1989-07-07 |
1992-08-18 |
Ciba-Geigy Corporation |
Topical formulations
|
US5356887A
(en)
*
|
1990-01-31 |
1994-10-18 |
Merck & Co., Inc. |
Pharmaceutical compositions containing insoluble calcium salts of amino-hydroxybutylidene bisphoshonic acids
|
US5204334A
(en)
*
|
1990-10-18 |
1993-04-20 |
Ciba-Geigy Corporation |
Benzoheterocyclylalkylaminoalkanediphosphonic acids, compositions thereof, and use thereof in the treatment of calcium metabolism disorders
|
KR100240358B1
(ko)
|
1991-02-26 |
2000-02-01 |
제이코버스 코넬리스 레이서 |
골다공증 치료방법
|
DE69216514T2
(de)
*
|
1991-08-27 |
1997-07-31 |
Ciba Geigy Ag |
N-Substituierte Aminomethandiphosphonsäuren
|
SK74594A3
(en)
*
|
1991-12-17 |
1995-01-12 |
Procter & Gamble Pharma |
Treatment for treating of osteoporosis
|
US5382658A
(en)
*
|
1992-04-03 |
1995-01-17 |
Allelix Biopharmaceuticals Inc. |
Stability-enhanced variants of parathyroid hormone
|
ES2111163T3
(es)
*
|
1992-06-30 |
1998-03-01 |
Procter & Gamble Pharma |
Uso de fosfonatos para el tratamiento de la osteoporosis.
|
US5409911A
(en)
*
|
1992-09-11 |
1995-04-25 |
Merck & Co., Inc. |
Prostaglandin analog for treating osteoporosis
|
US5366965A
(en)
*
|
1993-01-29 |
1994-11-22 |
Boehringer Mannheim Gmbh |
Regimen for treatment or prophylaxis of osteoporosis
|
US5449819A
(en)
*
|
1994-06-06 |
1995-09-12 |
Merck & Co., Inc. |
Process for removing waste pox, alendronate and its by products
|
FR2727629A1
(fr)
*
|
1994-12-06 |
1996-06-07 |
Sanofi Sa |
Trousse pour cycle de traitement de l'osteoporose
|
US20010051616A1
(en)
*
|
1995-02-17 |
2001-12-13 |
David B. Karpf |
Method of lessening the risk of vertebral fractures
|
KR19980702210A
(ko)
*
|
1995-02-17 |
1998-07-15 |
폴락 돈나 엘 |
비척추골 골절의 위험률을 감소시키는 방법
|
AU5973496A
(en)
|
1995-06-06 |
1996-12-24 |
Merck & Co., Inc. |
Bisphosphonate cement composition to prevent aseptic loosening of orthopedic implant devices
|
US20010031244A1
(en)
*
|
1997-06-13 |
2001-10-18 |
Chiesi Farmaceutici S.P.A. |
Pharmaceutical aerosol composition
|
US5994329A
(en)
*
|
1997-07-22 |
1999-11-30 |
Merck & Co., Inc. |
Method for inhibiting bone resorption
|
US6432932B1
(en)
|
1997-07-22 |
2002-08-13 |
Merck & Co., Inc. |
Method for inhibiting bone resorption
|
IT1303672B1
(it)
*
|
1998-07-28 |
2001-02-23 |
Nicox Sa |
Sali nitrati di farmaci attivi nei disordini ossei
|
JP4486256B2
(ja)
|
1998-10-22 |
2010-06-23 |
ザ・ジェネラル・ホスピタル・コーポレイション |
副甲状腺ホルモン(PTH)および副甲状腺ホルモン関連ペプチド(PTHrP)の生物活性ペプチドおよびペプチド誘導体
|
US6121253A
(en)
*
|
1998-11-20 |
2000-09-19 |
Merck Frosst Canada & Co. |
Prostaglandin conjugates for treating or preventing bone disease
|
US7057012B1
(en)
|
1998-12-31 |
2006-06-06 |
The General Hospital Corporation |
PTH functional domain conjugate peptides, derivatives thereof and novel tethered ligand-receptor molecules
|
ATE403678T1
(de)
*
|
1998-12-31 |
2008-08-15 |
Gen Hospital Corp |
Peptide, bestehend aus zwei funktionellen pth- domänen, die durch ein linkermolekül verknüpft sind, und derivate davon
|
US7534605B2
(en)
*
|
1999-06-08 |
2009-05-19 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem |
CD44 polypeptides, polynucleotides encoding same, antibodies directed thereagainst and method of using same for diagnosing and treating inflammatory diseases
|
ES2316354T3
(es)
|
1999-09-29 |
2009-04-16 |
The General Hospital Corporation |
Derivados polipeptidos de la hormona paratiroidea (pth).
|
US7022815B1
(en)
|
1999-09-29 |
2006-04-04 |
The General Hospital Corporation |
Polypeptide derivatives of parathyroid hormone (PTH)
|
WO2001023521A2
(en)
*
|
1999-09-29 |
2001-04-05 |
The General Hospital Corporation |
Polypeptide derivatives of parathyroid hormone (pth)
|
FR2801218B1
(fr)
*
|
1999-11-23 |
2001-12-28 |
Hoechst Marion Roussel Inc |
Compositions pharmaceutiques comprenant de la trimegestone, leurs procedes de preparation ainsi que le conditionnement primaire les renfermant
|
US6978894B2
(en)
|
1999-12-20 |
2005-12-27 |
Merck & Co., Inc. |
Blister package for pharmaceutical treatment card
|
US6677320B2
(en)
|
2000-01-20 |
2004-01-13 |
Hoffmann-La Roches Inc. |
Parenteral bisphosphonate composition with improved local tolerance
|
WO2001097752A2
(en)
*
|
2000-06-20 |
2001-12-27 |
The Trustees Of The University Of Pennsylvania |
Compositions comprising urokinase for modulating muscle contractility and angiogenisis
|
ATE304856T1
(de)
*
|
2000-06-20 |
2005-10-15 |
Novartis Pharma Gmbh |
Methode zur verabreichung von biphosphonaten
|
US20050147602A1
(en)
*
|
2000-10-19 |
2005-07-07 |
Maine Medical Center Research Institute |
Compositions, methods and kits relating to CTHRC1, a novel modulator of collagen matrix
|
US6630325B1
(en)
*
|
2000-10-19 |
2003-10-07 |
Maine Medical Center Research Institute |
Compositions, methods and kits relating to remodel
|
AU2002339843B2
(en)
*
|
2001-07-23 |
2007-12-06 |
The General Hospital Corporation |
Conformationally constrained parathyroid hormone (PTH) analogs
|
US20030119771A1
(en)
*
|
2001-08-22 |
2003-06-26 |
Rompaey Luc Van |
Modulators of bone homeostasis identified in a high-throughput screen
|
US20080057059A1
(en)
*
|
2001-11-09 |
2008-03-06 |
Novo Nordisk Healthcare A/G |
Pharmaceutical Composition Comprising Factor VII Polypeptides and Protein S Inhibitors
|
US20030124118A1
(en)
*
|
2001-11-27 |
2003-07-03 |
Rasmus Rojkjaer |
Pharmaceutical composition comprising factor VII polypeptides and protein S inhibitors
|
AU2002360619B2
(en)
*
|
2001-12-21 |
2006-10-05 |
Allergan Pharmaceuticals International Limited |
Method for the treatment of bone disorders
|
US20050070504A1
(en)
*
|
2001-12-21 |
2005-03-31 |
The Procter & Gamble Co. |
Risedronate compositions and their methods of use
|
EP1469860A4
(de)
*
|
2002-01-24 |
2005-09-07 |
Yissum Res Dev Co |
Antikrebskombination und deren verwendung
|
WO2003086415A1
(en)
*
|
2002-04-05 |
2003-10-23 |
Merck & Co., Inc. |
Method for inhibiting bone resorption with an alendronate and vitamin d formulation
|
CN100551377C
(zh)
|
2002-05-10 |
2009-10-21 |
弗·哈夫曼-拉罗切有限公司 |
用于治疗和预防骨质疏松症的二膦酸
|
US20060258726A1
(en)
*
|
2002-06-06 |
2006-11-16 |
Xavier Billot |
1,5-Disubstituted imidazolidin-2-one derivatives for use as ep4 receptor agonists in the treatment of eye and bone diseases
|
FR2841472B1
(fr)
|
2002-06-28 |
2006-02-24 |
Agronomique Inst Nat Rech |
Composition nutritionnelle ou therapeutique contenant le compose hesperidine ou l'un de ses derives
|
US20050031610A1
(en)
*
|
2002-07-19 |
2005-02-10 |
Tae-Wan Kim |
CD44-related fragments, compositions and methods
|
US20040138180A1
(en)
*
|
2002-10-03 |
2004-07-15 |
Barr Laboratories, Inc. |
Bisphosphonate composition and process for the preparation thereof
|
BE1015150A3
(nl)
*
|
2002-10-21 |
2004-10-05 |
Sonitron Nv |
Verbeterde transducent
|
PL212072B1
(pl)
*
|
2002-12-20 |
2012-08-31 |
Hoffmann La Roche |
Tabletka zawierająca jako substancję czynną do 250 mg kwasu ibandronowego oraz sposób jej wytwarzania
|
JP4541899B2
(ja)
*
|
2003-01-24 |
2010-09-08 |
ザ ジェネラル ホスピタル コーポレイション |
ラクタム架橋を有する、コンホメーションが制限された副甲状腺ホルモン(pth)アナログ
|
JP4334480B2
(ja)
*
|
2003-03-19 |
2009-09-30 |
ザ ジェネラル ホスピタル コーポレイション |
α−ヘリックス安定化剤を用いる高次構造的に制約された副甲状腺ホルモン
|
FR2853549B1
(fr)
|
2003-04-11 |
2007-11-09 |
Agronomique Inst Nat Rech |
Composition nutritionnelle ou therapeutique contenant le compose oleuropeine ou l'un de ses derives
|
US7910544B2
(en)
|
2003-07-17 |
2011-03-22 |
The General Hospital Corporation |
Conformationally constrained parthyroid hormone (PTH) analogs
|
WO2005018640A1
(en)
*
|
2003-08-20 |
2005-03-03 |
The Procter & Gamble Company |
Kit for treatment of upper gastrointestinal tract conditions
|
US7312353B2
(en)
|
2003-08-21 |
2007-12-25 |
Merck Frost Canada & Co. |
Cathespin cysteine protease inhibitors
|
WO2005027921A1
(en)
*
|
2003-09-19 |
2005-03-31 |
Pfizer Products Inc. |
Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and a bisphosphonate
|
US20050261250A1
(en)
*
|
2004-05-19 |
2005-11-24 |
Merck & Co., Inc., |
Compositions and methods for inhibiting bone resorption
|
HUE059143T2
(hu)
|
2004-05-24 |
2022-10-28 |
Theramex Hq Uk Ltd |
Kelátképzõ szert tartalmazó enterális szilárd orális biszfoszfonát dózisforma
|
UA87854C2
(en)
|
2004-06-07 |
2009-08-25 |
Мерк Энд Ко., Инк. |
N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators
|
EP1855674B1
(de)
|
2005-03-02 |
2014-07-16 |
Merck Sharp & Dohme Corp. |
Zusammensetzung zur hemmung von cathepsin k
|
EA200701997A1
(ru)
*
|
2005-03-17 |
2008-02-28 |
Элан Фарма Интернэшнл Лтд. |
Композиция из наночастиц бисфосфоната
|
AU2006336417A1
(en)
*
|
2005-05-10 |
2007-08-02 |
Elan Pharma International, Limited |
Nanoparticulate clopidogrel formulations
|
WO2006130839A1
(en)
*
|
2005-06-02 |
2006-12-07 |
U.S. Borax Inc. |
Prevention and treatment of osteochondrosis in animals and humans
|
US20080293677A1
(en)
*
|
2005-06-06 |
2008-11-27 |
Brookler Kenneth H |
Use of Alternating Amine and Non-Amine Bisphosphonate Combinations For Treating Osteoporosis
|
EP2054077A4
(de)
*
|
2006-08-04 |
2010-10-13 |
Gen Hospital Corp |
Polypeptidderivate des parathyroidhormons (pth)
|
US7781418B2
(en)
|
2006-12-14 |
2010-08-24 |
Isis Innovation Ltd. |
Composition for treating bone disorders
|
EP2650009B8
(de)
|
2007-08-01 |
2018-07-18 |
The General Hospital Corporation |
Screeningverfahren mit G-Protein-gekoppelten Rezeptoren und entsprechende Zusammensetzungen
|
MX2010006972A
(es)
|
2007-12-21 |
2010-08-26 |
Ligand Pharm Inc |
Moduladores selectivos de receptores de andrógenos (sarm) y usos de los mismos.
|
US20100068211A1
(en)
*
|
2008-02-08 |
2010-03-18 |
Bateman Ted A |
Use of antiresorptive compounds to prevent ionizing radiation-induced activation of osteoclasts and resulting bone loss
|
WO2010143193A1
(en)
|
2009-06-11 |
2010-12-16 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem, Ltd. |
Targeted liposomes comprising n-containing bisphosphonates and uses thereof
|
US8882740B2
(en)
*
|
2009-12-23 |
2014-11-11 |
Stryker Trauma Gmbh |
Method of delivering a biphosphonate and/or strontium ranelate below the surface of a bone
|
JP5941040B2
(ja)
|
2010-05-13 |
2016-06-29 |
ザ ジェネラル ホスピタル コーポレイション |
副甲状腺ホルモン類似体およびその使用
|
CN102372773B
(zh)
*
|
2010-08-11 |
2013-06-05 |
中国科学院生物物理研究所 |
人膀胱癌肿瘤标志物及其抗体和应用
|
US8791162B2
(en)
|
2011-02-14 |
2014-07-29 |
Merck Sharp & Dohme Corp. |
Cathepsin cysteine protease inhibitors
|
EP2716297B1
(de)
*
|
2011-03-11 |
2017-09-27 |
Tokyo University of Science Foundation |
D-glu-fniii14 polypeptid zur behandlung von krebs
|
PL2731591T3
(pl)
|
2011-07-13 |
2021-05-17 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. |
Liposomy zawierające bisfosfonian i środek amfipatyczny w wyniku ko-enkapsulacji
|
FR3005419B1
(fr)
|
2013-05-13 |
2015-09-04 |
Agronomique Inst Nat Rech |
Utilisation d'une association de deux composes pour le traitement et/ou la prevention de troubles osseux
|
AU2014332250B2
(en)
|
2013-10-08 |
2018-07-19 |
Merck Sharp & Dohme Corp. |
Cathepsin cysteine protease inhibitors
|
WO2015051479A1
(en)
|
2013-10-08 |
2015-04-16 |
Merck Sharp & Dohme Corp. |
Cathepsin cysteine protease inhibitors
|
WO2015120580A1
(en)
|
2014-02-11 |
2015-08-20 |
Merck Sharp & Dohme Corp. |
Cathepsin cysteine protease inhibitors
|
PL407922A1
(pl)
|
2014-04-16 |
2015-10-26 |
Wrocławskie Centrum Badań Eit + Spółka Z Ograniczoną Odpowiedzialnością |
Nowe bisfosfoniany i ich zastosowanie
|
BR112016027778A2
(pt)
|
2014-05-30 |
2017-08-15 |
Pfizer |
Usos de derivados de carbonitrila, sua combinação e sua composição farmacêutica
|
BR112017000710B1
(pt)
|
2014-07-15 |
2024-02-27 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem |
Polipeptídeo isolado, composição de matéria, e, uso do polipeptídeo isolado ou da composição da matéria
|
FR3066919B1
(fr)
|
2017-06-06 |
2019-08-02 |
Institut National De La Recherche Agronomique (Inra) |
Composition de phycocyanine pour son utilisation pour inhiber la resorption osseuse.
|
WO2023275715A1
(en)
|
2021-06-30 |
2023-01-05 |
Pfizer Inc. |
Metabolites of selective androgen receptor modulators
|